Michael D. Axelson

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.7K citations · Full text

Checkmate 142, Medicine, Colorectal Cancer +8

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

Michael D. Axelson, Ke Liu, Xiaoping Jiang et al. · Clinical Cancer Research · 2013 · 182 citations · Full text

Regulatory Considerations, U.s. Food, Medicine +12

Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

Michael J. Overman, Scott Kopetz, Ray McDermott et al. · Journal of Clinical Oncology · 2016 · 136 citations

Immunology, Sudden Death, Pathology +21

Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin “flushes”

Majed A. Refaai, Theodore E. Warkentin, Michael D. Axelson et al. · Thrombosis and Haemostasis · 2007 · 44 citations

Thrombosis, Venous Thrombosis, Blood Platelet +11

Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data

Louis E. Fernandes, Caroline G. Epstein, Alexandria M. Bobe et al. · Clinical Breast Cancer · 2020 · 23 citations

Breast Oncology, Cancer Detection, Medicine +10